Clinical Trial Update: BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) [Phase 2]

View source ↗

Summary

Phase II trial of BAY 43-9006 (sorafenib) in non-small cell lung cancer has completed. Results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BAY 43-9006 (sorafenib) (sorafenib)

Snippet

Sponsor: Bayer | Conditions: Cancer, Carcinoma, Non-Small Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2010-04-08